Pharmaceutical - Johnson & Johnson, Novartis


Current filters:

Johnson & JohnsonNovartis

Popular Filters

ESMO 2014: Novartis’ Afinitor; and Janssen’s Zytiga

ESMO 2014: Novartis’ Afinitor; and Janssen’s Zytiga


Swiss pharma major Novartis on Saturday presented final results on overall survival (OS) from a Phase…

AfinitorJanssenJohnson & JohnsonNovartisOncologyPharmaceuticalResearchSpainZytiga

EC fines J&J and Novartis 16 million euros over fentanyl pay-for-delay deal

EC fines J&J and Novartis 16 million euros over fentanyl pay-for-delay deal


The European Commission has imposed fines of 10.8 million euros ($14.8 million) on the US health care…

EuropefentanylFinancialJohnson & JohnsonNeurologicalNovartisPatentsPharmaceuticalSandoz

Pharma figures high in EU R&D Investment Scoreboard, but led by US firms


Though not topping the league table, the pharmaceutical industry had a number of drugmakers among the…

EuropeFinancialGlaxoSmithKlineJohnson & JohnsonMerck & CoNorth AmericaNovartisPfizerPharmaceuticalResearchRocheSanofi

Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib


Among presentations over the weekend at the Congress of European Hematology Association (EHA) being held…

AbbVieBristol-Myers SquibbelotuzumabibrutinibIncyteJakaviJanssenJohnson & JohnsonNovartisOncologyPharmaceuticalPharmacyclicsResearch

Sales of psoriasis drugs to be worth $7.4 billion by 2020


The psoriasis market experienced approximately 36.5 million prevalent cases across the USA, France, Germany,…

AbbVieAmgenAsia-PacificDermatologicalsEnbrelEuropeHumiraJohnson & JohnsonMarkets & MarketingNorth AmericaNovartisPfizerPharmaceuticalsecukinumabStelara Injectiontofacitinib

EU Commission sends antitrust complaint to Johnson & Johnson and Novartis


The European Commission has informed US health care giant Johnson & Johnson (NYSE: JNJ) and Swiss drug…

DuragesicEuropefentanylGenericsJanssen-CilagJohnson & JohnsonLegalMarkets & MarketingNeurologicalNovartisPatentsPharmaceuticalSandoz

Genmab in collaboration with Janssen for DuoBody platform


Denmark-based Genmab A/S (OMX: GEN) says it has entered into a collaboration with Janssen Biotech, a…

BiotechnologyDuoBodyGenmabJanssen BiotechJohnson & JohnsonLicensingNovartisPharmaceutical

More news at EULAR from Novartis, J&S and B-MS


Highlights presented at the annual congress of the European League Against Rheumatism (EULAR 2012), in…

Anti-Arthritics/RheumaticsBristol-Myers SquibbIlarisJohnson & JohnsonNovartisOrenciaPharmaceuticalResearchSimponi InjectionStelara Injection

Positive NICE news for Gilenya for MS and Incivo for hep C


There was good news from the UK drugs watchdog the Institute for Health and Clinical Excellence (NICE)…

Anti-viralsEuropeGilenyaIncivoJanssen-CilagJohnson & JohnsonNeurologicalNovartisPharmaceuticalPricingRegulation



Back to top